Great paper MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenua… https://t.co/p2ZsVvYXqo
@carl_jurassic This was our first paper on COVID https://t.co/ekHys5KVuf
RT @weldeiry: I am please to share that our MEKi-COVID paper is published: MEK inhibitors reduce cellular expression of ACE2, pERK, pRb whi…
RT @weldeiry: Our collaborative MEKi-COVID paper featured on cover of latest issue of @Oncotarget @BrownUCancer @BrownUResearch @BrownMedic…
RT @weldeiry: I am please to share that our MEKi-COVID paper is published: MEK inhibitors reduce cellular expression of ACE2, pERK, pRb whi…
RT @weldeiry: Our collaborative MEKi-COVID paper featured on cover of latest issue of @Oncotarget @BrownUCancer @BrownUResearch @BrownMedic…
RT @weldeiry: I am please to share that our MEKi-COVID paper is published: MEK inhibitors reduce cellular expression of ACE2, pERK, pRb whi…
RT @weldeiry: I am please to share that our MEKi-COVID paper is published: MEK inhibitors reduce cellular expression of ACE2, pERK, pRb whi…
Our paper was published in November, 2020 and so you can see the latest version https://t.co/BnQmWDvV00
MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection. https://t.co/uEeUEgPveL
MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection. by Zhou L, Huntington K, Zhang S, Carlsen L, So EY, Parker C, Sahin I, Safra…
MEKi suppress COVID-19 infectivity, inflammatory cytokines ยุคทอง oncodrugs ขิงๆ
RT @weldeiry: Our collaborative MEKi-COVID paper featured on cover of latest issue of @Oncotarget @BrownUCancer @BrownUResearch @BrownMedic…
RT @weldeiry: Our collaborative MEKi-COVID paper featured on cover of latest issue of @Oncotarget @BrownUCancer @BrownUResearch @BrownMedic…
RT @weldeiry: Our collaborative MEKi-COVID paper featured on cover of latest issue of @Oncotarget @BrownUCancer @BrownUResearch @BrownMedic…
RT @weldeiry: Our collaborative MEKi-COVID paper featured on cover of latest issue of @Oncotarget @BrownUCancer @BrownUResearch @BrownMedic…
Our collaborative MEKi-COVID paper featured on cover of latest issue of @Oncotarget @BrownUCancer @BrownUResearch @BrownMedicine @FoxChaseCancer @VerastemOncolog @RIHospital the featured result shows SARS-CoV-2 pseudovirus infectivity of lung cells that ca
The cover for issue 46 of Oncotarget features Figure 6, by Zhou, et al. https://t.co/YnoC5MG87U
MAPK #Comprehensive antiviral platform #NK #oncology #cancer #COVID19 https://t.co/uyljdcCMHT
RT @weldeiry: I am please to share that our MEKi-COVID paper is published: MEK inhibitors reduce cellular expression of ACE2, pERK, pRb whi…
RT @weldeiry: I am please to share that our MEKi-COVID paper is published: MEK inhibitors reduce cellular expression of ACE2, pERK, pRb whi…
RT @weldeiry: I am please to share that our MEKi-COVID paper is published: MEK inhibitors reduce cellular expression of ACE2, pERK, pRb whi…
RT @weldeiry: I am please to share that our MEKi-COVID paper is published: MEK inhibitors reduce cellular expression of ACE2, pERK, pRb whi…
Great work...
I am please to share that our MEKi-COVID paper is published: MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to... | Oncotarget @Oncotarget https://t